NEW YORK (Reuters Health)—Certolizumab pegol, a humanized anti-TNF antibody fragment conjugated to polyethylene glycol, is effective for treating early rheumatoid arthritis (RA) with poor prognostic factors, according to results from the C-OPERA study. Certolizumab is approved in the U.S. and other countries for treating inflammatory diseases, including RA, but its effectiveness in methotrexate-naïve early RA…
Fulfilling ‘Three Wishes’ Helps ICU Staff Honor Dying Patients
(Reuters Health)—Doctors and nurses in a Canadian intensive care unit found that asking dying patients—or their families—to make three simple wishes, and then fulfilling those wishes, helped bring peace to the end-of-life process and ease grief. Patients and families were invited to participate in the “Three Wishes Project” after a decision was made to withdraw…
Tofacitinib Not Tied to More Malignancies in RA Patients
NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…
Bigger May Not Be Better for China’s ‘Super Hospitals’
ZHENGZHOU, China (Reuters)—Just before midnight, the pavement outside the glowing high-rise towers of the First Affiliated Hospital of Zhengzhou University is littered with slumbering bodies. Splayed on colourful mats or tucked into folding cots, these are patients’ relatives. Inside, beds line hallways and crowd elevator lobbies, while relatives share gurneys with patients and doze in…
Family History Not Linked to Clinical Presentation, Treatment Response of RA
NEW YORK (Reuters Health)—Having a family history of rheumatoid arthritis (RA) does not appear to influence the clinical presentation or treatment response of RA to standard medications, researchers from Sweden report. “At first we were a bit surprised by our findings,” Dr. Thomas Frisell from Karolinska Institutet in Stockholm told Reuters Health by email. “Patients…
Teriparatide to Denosumab Switch Helpful in Osteoporosis
NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…
On Research Review Boards, Conflict-of-Interest Reporting Improves
(Reuters Health)—Many doctors who serve on hospital panels overseeing the ethics and safety of human research trials have industry relationships that may compromise their objectivity, but reporting these conflicts has become more common over the past 10 years, according to a new study. Physicians who serve on so-called institutional review boards (IRBs) may also be…
Greece Bans Export of 25 Drugs after Pharmacists’ Supply Warnings
ATHENS (Reuters)—Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings by pharmacists that they faced difficulties in securing some supplies. A ministry spokeswoman said the Greek drugs regulator had told a meeting at the ministry on Friday—when the pharmacists made their warnings—that there had…
Secukinumab Effective for Treating Psoriatic Arthritis
NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…
U.S. House Passes Bill to Speed New Drugs to Market
WASHINGTON (Reuters)—The U.S. House of Representatives on Friday passed a bill aimed at speeding new drugs to the market after lawmakers defeated last-minute amendments that threatened to derail it. The House voted 344 to 77 in favor of the bill, known as the 21st Century Cures Act, which would require the FDA to streamline the…
- « Previous Page
- 1
- …
- 565
- 566
- 567
- 568
- 569
- …
- 808
- Next Page »